REGENXBIO Inc. Files 8-K Report
Ticker: RGNX · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1590877
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
TL;DR
REGENXBIO filed an 8-K, likely containing routine updates or exhibits.
AI Summary
On December 9, 2024, REGENXBIO Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates that REGENXBIO Inc. has submitted a report to the SEC, which may contain updates or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- December 9, 2024 (date) — Date of Report
- 001-37553 (other) — Commission File Number
- 47-1851754 (other) — IRS Employer Identification No.
- 9804 Medical Center Drive (other) — Principal Executive Offices Address
- Rockville, Maryland (other) — Principal Executive Offices Location
- 20850 (other) — Principal Executive Offices Zip Code
FAQ
What is the primary purpose of this 8-K filing by REGENXBIO Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 9, 2024.
What is REGENXBIO Inc.'s Commission File Number?
REGENXBIO Inc.'s Commission File Number is 001-37553.
Where are REGENXBIO Inc.'s principal executive offices located?
REGENXBIO Inc.'s principal executive offices are located at 9804 Medical Center Drive, Rockville, Maryland, 20850.
Does the filing mention any specific financial results or material agreements?
The provided text of the filing does not detail specific financial results or material agreements; it primarily indicates the filing of financial statements and exhibits.
Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-12-09 16:45:54
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
- $150.0 million — ng an aggregate offering price of up to $150.0 million (the "Shares"). The Company will file a
Filing Documents
- d837203d8k.htm (8-K) — 30KB
- d837203dex11.htm (EX-1.1) — 158KB
- d837203dex51.htm (EX-5.1) — 8KB
- d837203dex991.htm (EX-99.1) — 44KB
- g837203g1207024953393.jpg (GRAPHIC) — 1KB
- g837203g1207024953548.jpg (GRAPHIC) — 6KB
- g837203g1207025114990.jpg (GRAPHIC) — 3KB
- g837203g1207025115271.jpg (GRAPHIC) — 21KB
- g837203g1207025115513.jpg (GRAPHIC) — 19KB
- 0001193125-24-273467.txt ( ) — 486KB
- rgnx-20241209.xsd (EX-101.SCH) — 3KB
- rgnx-20241209_lab.xml (EX-101.LAB) — 17KB
- rgnx-20241209_pre.xml (EX-101.PRE) — 11KB
- d837203d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Sales Agreement, dated as of December 9, 2024, between Leerink Partners LLC and REGENXBIO Inc. 5.1 Opinion of Covington & Burling LLP. 23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1). 99.1 Press release dated November 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 9, 2024 REGENXBIO Inc. By: /s/ Patrick J. Christmas II Name: Patrick J. Christmas II Title: Executive Vice President, Chief Legal Officer